|
1
|
Salani R and Bristow RE: Surgical
management of epithelial ovarian cancer. Clin Obstet Gynecol.
55:75–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haber JE and Heyer WD: The fuss about
Mus81. Cell. 107:551–554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boddy MN, Lopez-Girona A, Shanahan P,
Interthal H, Heyer WD and Russell P: Damage tolerance protein Mus81
associates with the FHA1 domain of checkpoint kinase Cds1. Mol Cell
Bio. 20:8758–8766. 2000. View Article : Google Scholar
|
|
4
|
Hanada K, Budzowska M, Davies SL, van
Drunen E, Onizawa H, Beverloo HB, Maas A, Essers J, Hickson ID and
Kanaar R: The structure-specific endonuclease Mus81 contributes to
replication restart by generating double-strand DNA breaks. Nat
Struct Mol Biol. 14:1096–1104. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sarbajna S and West SC: Holliday junction
processing enzymes as guardians of genome stability. Trends Biochem
Sci. 39:409–419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xie S, Zheng H, Wen X, Sun J, Wang Y, Gao
X, Guo L and Lu R: MUS81 is associated with cell proliferation and
cisplatin sensitivity in serous ovarian cancer. Biochem Bioph Res
Commun. 476:493–500. 2016. View Article : Google Scholar
|
|
7
|
McPherson JP, Lemmers B, Chahwan R, Pamidi
A, Migon E, Matysiak-Zablocki E, Moynahan ME, Essers J, Hanada K,
Poonepalli A, et al: Involvement of mammalian Mus81 in genome
integrity and tumor suppression. Science. 304:1822–1826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dendouga N, Gao H, Moechars D, Janicot M,
Vialard J and McGowan CH: Disruption of murine Mus81 increases
genomic instability and DNA damage sensitivity but does not promote
tumorigenesis. Mol Cell Biol. 25:7569–7579. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ledermann JA: PARP inhibitors in ovarian
cancer. Ann Oncol. 27 Suppl 1:i40–i44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gadducci A and Guerrieri ME: PARP
inhibitors in epithelial ovarian cancer: State of art and
perspectives of clinical research. Anticancer Res. 36:2055–2064.
2016.PubMed/NCBI
|
|
11
|
Liu FW and Tewari KS: New targeted agents
in gynecologic cancers: Synthetic lethality, homologous
recombination deficiency, and PARP inhibitors. Curr Treat Option
Oncol. 17:122016. View Article : Google Scholar
|
|
12
|
McLachlan J and Banerjee S: Olaparib for
the treatment of epithelial ovarian cancer. Expert Opin
Pharmacother. 17:995–1003. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gunderson CC and Moore KN: Olaparib: An
oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian
cancer. Future Oncol. 11:747–757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Negrini S, Gorgoulis VG and Halazonetis
TD: Genomic instability - an evolving hallmark of cancer. Nat Rev
Mol Cell Biol. 11:220–228. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grady WM: Genomic instability and colon
cancer. Cancer Metastasis Rev. 23:11–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tercero JA, Longhese MP and Diffley JF: A
central role for DNA replication forks in checkpoint activation and
response. Mol Cell. 11:1323–1336. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sabatinos SA, Green MD and Forsburg SL:
Continued DNA synthesis in replication checkpoint mutants leads to
fork collapse. Mol Cell Biol. 32:4986–4997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen XB, Melchionna R, Denis CM, Gaillard
PH, Blasina A, Van de Weyer I, Boddy MN, Russell P, Vialard J and
McGowan CH: Human Mus81-associated endonuclease cleaves holliday
junctions in vitro. Mol Cell. 8:1117–1127. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boddy MN, Gaillard PH, McDonald WH,
Shanahan P, Yates JR III and Russell P: Mus81-Eme1 are essential
components of a holliday junction resolvase. Cell. 107:537–548.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu H, Martin MM, Regairaz M, Huang L, You
Y, Lin CM, Ryan M, Kim R, Shimura T, Pommier Y and Aladjem MI: The
DNA repair endonuclease Mus81 facilitates fast DNA replication in
the absence of exogenous damage. Nat Commun. 6:67462015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blow JJ and Dutta A: Preventing
re-replication of chromosomal DNA. Nat Rev Mol Cell Biol.
6:476–486. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun J, Fernandez-Cid A, Riera A, Tognetti
S, Yuan Z, Stillman B, Speck C and Li H: Structural and mechanistic
insights into Mcm2-7 double-hexamer assembly and function. Genes
Dev. 28:2291–2303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cortez D, Glick G and Elledge SJ:
Minichromosome maintenance proteins are direct targets of the ATM
and ATR checkpoint kinases. Proc Natl Acad Sci USA. 101:pp.
10078–10083. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu M, Ba Z, Costa-Nunes P, Wei W, Li L,
Kong F, Li Y, Chai J, Pontes O and Qi Y: IDN2 interacts with RPA
and facilitates DNA double-strand break repair by homologous
recombination in arabidopsis. Plant Cell. 29:589–599. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maher RL, Branagan AM and Morrical SW:
Coordination of DNA replication and recombination activities in the
maintenance of genome stability. J Cell Biochem. 112:2672–2682.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mao P, Liu J, Zhang Z, Zhang H, Liu H, Gao
S, Rong YS and Zhao Y: Homologous recombination-dependent repair of
telomeric DSBs in proliferating human cells. Nat Commun.
7:121542016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan DS, Rothermundt C, Thomas K, Bancroft
E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB and Gore
ME: ‘BRCAness’ syndrome in ovarian cancer: A case-control study
describing the clinical features and outcome of patients with
epithelial ovarian cancer associated with BRCA1 and BRCA2
mutations. J Clin Oncol. 26:5530–5536. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krajewska M, Fehrmann RS, de Vries EG and
van Vugt MA: Regulators of homologous recombination repair as novel
targets for cancer treatment. Front Genet. 6:962015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Remus D, Beuron F, Tolun G, Griffith JD,
Morris EP and Diffley JF: Concerted loading of MCM2-7 double
hexamers around DNA during DNA replication origin licensing. Cell.
139:719–730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Labib K: How do Cdc7 and cyclin-dependent
kinases trigger the initiation of chromosome replication in
eukaryotic cells? Genes Dev. 24:1208–1219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tercero JA, Labib K and Diffley JF: DNA
synthesis at individual replication forks requires the essential
initiation factor Cdc45p. EMBO J. 19:2082–2093. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moyer SE, Lewis PW and Botchan MR:
Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for
the eukaryotic DNA replication fork helicase. Proc Natl Acad Sci
USA. 103:pp. 10236–10241. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rodriguez R, Gagou ME and Meuth M:
Apoptosis induced by replication inhibitors in Chk1-depleted cells
is dependent upon the helicase cofactor Cdc45. Cell Death Differ.
15:889–898. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Köhler C, Koalick D, Fabricius A, Parplys
AC, Borgmann K, Pospiech H and Grosse F: Cdc45 is limiting for
replication initiation in humans. Cell Cycle. 15:974–985. 2016.
View Article : Google Scholar : PubMed/NCBI
|
